Reaction

Bronchiolitis reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,499 reports · 64 co-occurring drugs

As of the last recalculation, Bronchiolitis appears in 3,499 FAERS reports alongside 64 co-occurring drug terms. The strongest observed disproportionality signal is PALIVIZUMAB (PRR 775.2).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Palivizumab	1,274	775.2	845.7
Vigabatrin	45	18.6	18.6
Captopril	25	15.6	15.6
Valproate Sodium	51	14.9	14.9
Calcitriol Capsules 0.25 Mcg	33	9.9	9.9
Calcitriol Capsules 0.5 Mcg	33	9.9	9.9
Calcitriol	33	9.8	9.8
Mepolizumab	77	9.4	9.4
Lanreotide Acetate	12	9.1	9.1
Nicotine Polacrilex Mini	22	8.8	8.8
Nicotine Polarilex	22	8.8	8.8
Ciclesonide	18	7.9	7.9
Telmisartan	23	7.7	7.7
Budesonide	70	7.2	7.2
Phytonadione	9	6.3	6.3
Zidovudine	14	6.2	6.3
Busulfan	16	6.1	6.1
Clobazam	24	5.9	5.9
Rosuvastatin Calcium	26	5.5	5.5
Azithromycin	36	5.4	5.4
Azithromycin Monohydrate	37	5.3	5.3
Tiotropium Bromide Inhalation Spray	10	5.3	5.3
Albuterol	101	5.1	5.1
Azithromycin Dihydrate	49	5.0	5.0
Melphalan	19	5.0	5.0
Daspone	8	4.9	4.9
Dapsone Gel, 5%	8	4.9	4.9
Melphalan Hydrochloride	20	4.8	4.8
Budesonide And Formoterol Fumarate Dihydrate	76	4.7	4.7
Ursosiol	15	4.6	4.6
Rabeprazole Sodium	21	4.6	4.6
Phenobarbital	11	4.5	4.5
Dapsone	8	4.5	4.5
Imatinib	13	4.4	4.4
Ursodiol	16	4.4	4.4
Tiotropium Bromide	97	4.3	4.3
Fludarabine Phosphate	28	4.3	4.3
Irbesartan	31	4.2	4.2
Doxazosin Mesylate	23	3.8	3.8
Sirolimus	8	3.5	3.5
Bendamustine Hcl	9	3.5	3.5
Omalizumab	49	3.5	3.5
Nicotine Polacrilex	22	3.4	3.4
Nicotine	23	3.4	3.4
Bosutinib	5	3.3	3.3
Azacitidine For	10	3.3	3.3
Zonisamide	8	3.2	3.2
Carfilzomib	15	3.2	3.2
Thiotepa	5	3.1	3.1
Bosentan	26	3.1	3.1
Obinutuzumab	8	2.9	2.9
Bortezomib	41	2.7	2.7
Nivolumab	42	2.6	2.6
Azacitidine	12	2.4	2.4
Canakinumab	4	2.2	2.2
Atezolizumab	14	2.1	2.1
Benralizumab	7	2.1	2.1
Selinexor	3	2.1	2.1
Erlotinib Hydrochloride	4	1.9	1.9
Polatuzumab Vedotin	3	1.8	1.8
Ipilimumab	13	1.8	1.8
Elexacaftor, Tezacaftor, And Ivacaftor	3	1.4	1.4
Somatropin	13	1.1	1.1
Pirfenidone	6	0.9	0.9

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.